1. In Vivo

Sanofi Reworks R&D To Tackle Risk, Meet Unmet Need

A newly launched grass roots campaign aimed at academics and the biotech community offers some insight into Sanofi's reinvigorated R&D organization, which is meant to be more flexible and entrepreneurial. Despite the potential upheaval caused by its recent $20.1 billion acquisition of Genzyme, Sanofi is talking up a handful of targeted areas of high unmet need and commensurately huge opportunities that are a critical part of its long-range strategy.

Ever since December 2010, when Sanofi, which recently dropped the Aventis portion of its name, announced former National Institutes of Health Director Elias Zerhouni was spearheading the French pharma's R&D initiatives, outsiders have expected major changes in how the firm will approach innovation. A newly launched grass roots campaign aimed at academics and the biotech community offers some insight into the French pharma's reinvigorated R&D organization, which is meant to be more flexible and entrepreneurial. Despite the potential upheaval caused by its recent $20.1 billion acquisition of Genzyme Corp., Sanofi is talking up a handful of targeted areas of high unmet need and commensurately huge opportunities that are a critical part of its long-range strategy. [See Deal] ( See "Sanofi/Genzyme: Emblematic of What Big Pharma's Buying Now," IN VIVO, March 2011 Also see "Sanofi/Genzyme: Emblematic of What Big Pharma's Buying Now " - In Vivo, 1 March, 2011..)

Sanofi actually announced its reworked R&D structure in June 2009, about six months after Christopher Viehbacher took over as CEO....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.